Hepatic Disorders With the Use of Remdesivir for Coronavirus 2019

Czarska-Thorley

Goldman, 2020, Remdesivir for 5 or 10 days in patients with severe Covid-19, N Engl J Med, 10.1056/NEJMoa2015301

Antinori, 2020, Compassionate remdesivir treatment of severe Covid-19 pneumonia in intensive care unit (ICU) and non-ICU patients: clinical outcome and differences in post-treatment hospitalisation status, Pharmacol Res, 158, 104899, 10.1016/j.phrs.2020.104899

Grein, 2020, Compassionate use of remdesivir for patients with severe Covid-19, N Engl J Med, 382, 2327, 10.1056/NEJMoa2007016

Wang, 2020, Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial, Lancet, 395, 1569, 10.1016/S0140-6736(20)31022-9

Lindquist, 2008, VigiBase, the WHO Global ICSR Database System: basic facts, Drug Information Journal, 42, 409, 10.1177/009286150804200501

Faillie, 2019, Case-non-case studies: principle, methods, bias and interpretation, Therapie, 74, 225, 10.1016/j.therap.2019.01.006